Skip to main content

Table 3 Secondary outcomes

From: Prognosis of mechanically ventilated patients with COVID-19 after failure of high-flow nasal cannula: a retrospective cohort study

Outcomes

MV (n = 51)

HFNC-F (n = 107)

p-value

Unadjusted OR (95% CI)

Adjusted OR (95% CI)

ICU mortality at day 28a

8 (15.7)

15 (14.0)

0.781

0.89 (0.38–2.11)

1.31 (0.46–3.71)

Successful ventilator weaning by day 28b

25 (49.0)

63 (58.9)

0.243

1.44 (0.91–2.29)

1.44 (0.88–2.35)

ICU discharge at day 28c

28 (54.9)

60 (56.1)

0.890

1.12 (0.72–1.75)

1.05 (0.66–1.70)

Prone position at day 28d

23 (45.1)

61 (72.6)

0.161

1.30 (0.80–2.09)

1.19 (0.73–1.95)

ECMO at day 28e

9 (17.6)

6 (5.6)

0.021

0.30 (0.11–0.83)

0.34 (1.12–0.98)

CRRT at day 28f

9 (17.6)

10 (9.3)

0.134

0.49 (0.20–1.21)

0.87 (0.29–2.63)

Duration, day

     

 Mechanical ventilator duration

13.00 [7.00, 32.00]

12.00 [6.00, 25.00]

0.849

  

 ICU length of stay

14.00 [8.00, 35.00]

16.00 [8.00, 34.00]

0.762

  

 Hospital length of stay

27.00 [16.00, 95.00]

31.00 [17.00, 46.00]

0.320

  
  1. Data are reported as number (percentage), median [interquartile range], or mean ± standard deviation. MV: mechanical ventilation; HFNC: high-flow nasal cannula; ECMO: extracorporeal membrane oxygenation; CRRT: continuous renal replacement therapy; ICU: intensive care unit
  2. a Multivariate model adjusted for age, comorbidities (chronic neurologic disease and chronic kidney disease), anticoagulation, use of remdesivir, and CRRT.
  3. b Multivariate model adjusted for ex-smoker, current smoker, COVID-19 vaccination, prone position, and ECMO.
  4. c Multivariate model adjusted for body mass index, chronic kidney disease, anticoagulation, prone position, and ECMO.
  5. d Multivariate model adjusted for age, body mass index, transplantation status, remdesivir, and tocilizumab
  6. e Multivariate model adjusted for age, comorbidities (chronic lung disease and chronic liver disease), and tocilizumab
  7. f Multivariate model adjusted for age, body mass index, comorbidities (chronic kidney disease and solid cancer), anticoagulation, steroid, tocilizumab, procalcitonin, and PaO2/FiO2 ratio